Sugi Predict

Sugi Predict / Compounds / SCHEMBL950272

SCHEMBL950272

SCHEMBL950272

COC(OC)C(=O)C=CN(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 5/20 0.45
▸ CYP1A2 P05177 4/20 0.45
▸ CYP2C9 P11712 3/20 0.45
▸ HPGD P15428 7/20 0.42
▸ MEN1 O00255 5/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ LMNA P02545 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 6/20 0.41
▸ L3MBTL1 Q9Y468 3/20 0.41
▸ ALOX12 P18054 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ TDP1 Q9NUW8 3/20 0.40
▸ RECQL P46063 3/20 0.35
▸ GAA P10253 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ POLB P06746 3/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL950271 1.00 CYP2C19 (0.45) CYP2C19CYP1A2CYP2C9HPGDMEN1
SCHEMBL5962069 0.92 CYP2C19 (0.41) CYP2C19CYP1A2CYP2C9HPGDMEN1
SCHEMBL13735641 0.90 CYP1A2 (0.43) CYP2C19CYP1A2CYP2C9HPGDMEN1
SCHEMBL13735642 0.90 CYP1A2 (0.43) CYP2C19CYP1A2CYP2C9HPGDMEN1
SCHEMBL25623926 0.82 CYP2C19 (0.41) CYP2C19CYP1A2CYP2C9HPGDMEN1
SCHEMBL16187811 0.80 CYP2C19 (0.51) CYP2C19CYP1A2CYP2C9HPGDMEN1
SCHEMBL314333 0.73 CYP1A2 (0.44) CYP2C19CYP1A2CYP2C9HPGDMEN1
SCHEMBL4264708 0.73 KEAP1 (0.33) —
SCHEMBL16865867 0.73 KEAP1 (0.33) —
SCHEMBL314334 0.73 CYP1A2 (0.44) CYP2C19CYP1A2CYP2C9HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118273125-A Production process of shrink-proof woven fabric 蒋全涛 2024-07-02 — — CN claimed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 — — US disclosed
US-20250313572-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2025-10-09 — — US disclosed
WO-2025106634-A1 MCL-1 INHIBITOR COMPOUNDS AND USE IN ANTIBODY DRUG CONJUGATES GENENTECH, INC. (US) 2025-05-22 — — WO disclosed
US-20250092062-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2025-03-20 — — US disclosed
EP-3728256-B1 PYRAZOLOPYRIDINE-DIAMIDES, THEIR USE AS INSECTICIDE AND PROCESSES FOR PREPARING THE SAME PI INDUSTRIES LTD (IN) 2024-10-02 — — EP disclosed
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2024-07-11 — — US disclosed
US-12024510-B2 Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same PI INDUSTRIES LTD. (IN) 2024-07-02 — — US disclosed
CN-118273125-A Production process of shrink-proof woven fabric 蒋全涛 2024-07-02 — — CN disclosed
US-20230399340-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2023-12-14 — — US disclosed
EP-0660827-B1 HETEROCYCLIC COMPOUNDS WITH PARASITICAL ACTIVITY ZENECA LTD (GB) 1997-04-16 — — EP disclosed
EP-0727998-A4 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 1997-03-19 — — EP disclosed
US-5593992-A CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1997-01-14 — — US disclosed
US-5593991-A ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR SMITHKLINE BEECHAM CORPORATION 1997-01-14 — — US disclosed
EP-0727998-A1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1996-08-28 — — EP disclosed
WO-1996021452-A1 CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE SMITHKLINE BEECHAM CORPORATION (US) 1996-07-18 — — WO disclosed
EP-0660827-A1 HETEROCYCLIC COMPOUNDS WIHT PARASITICAL ACTIVITY. ZENECA LTD (GB) 1995-07-05 — — EP disclosed
WO-1995013067-A1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1995-05-18 — — WO disclosed
WO-1994029300-A1 PYRAZOLE FUNGICIDES 3-SUBSTITUTED BY A HETEROCYCLIC RING RHONE POULENC AGROCHIMIE (FR) 1994-12-22 — — WO disclosed
WO-1994006777-A1 HETEROCYCLIC COMPOUNDS WIHT PARASITICAL ACTIVITY ZENECA LIMITED (GB) 1994-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 CYP2C19 3160/4885CYP1A2 2446/4885CYP2C9 2500/4885
US-12024510-B2 Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same DDT, QDPR, CYP1A1 CYP2C19 120/4885CYP1A2 9/4885CYP2C9 65/4885
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX CYP2C19 3314/4885CYP1A2 2158/4885CYP2C9 2339/4885
US-20250092062-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 CYP2C19 3160/4885CYP1A2 2446/4885CYP2C9 2500/4885
US-20250313572-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 CYP2C19 3160/4885CYP1A2 2446/4885CYP2C9 2500/4885
US-20230399340-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 CYP2C19 3160/4885CYP1A2 2446/4885CYP2C9 2500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.